Skip to main content

Table 1 Baseline characteristics of the RTX-treated SLE and AAV patients

From: First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

  SLE (n = 66) AAV (n = 22)
Clinical features
 Females (n, (%)) 60 (90.9) 12 (54.5)
 Age (median (IQR)) 36.3 (29.8–50.3) 62.0 (44.0–70.5)
 Disease duration (median (IQR)) 7.9 (2.6–14.3) 1.5 (0–6.5)
Disease activity
 SLEDAI-2Ka (n = 65) (median (IQR)) 12.0 (7.0–16.0)
 BVAS (n = 17) (median (IQR)) 15.0 (10.5–22.5)
Rituximab treatment regimens
 375 mg/m2 × 4 weekly infusions (n, %) 38 (57.6) 5 (22.7)
 1 g 2 weeks apart (n, %) 24 (36.4) 13 (59.1)
 500 mg 2 weeks apart (n, %) 4 (6.1) 3 (13.6)
Concomitant treatments
 IV cyclophosphamide (n, %) 36 (54.5) 10 (45.4)
 IV 6-methylprednisolone (n, %) 37 (56.1) 4 (18.2)
  1. IQR Interquartile range, SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000, BVAS Birmingham Vasculitis Activity Index, IV Intravenous
  2. aOne patient (indication peripheral polyneuropathy) was excluded from the calculation